TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02727387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEMIRI
Description: Window therapy frontline for VHR patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFO
Description: Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETO
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUMEL
Description: Consolidation phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIN
Description: Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
Study: NCT01771848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
Study: NCT01648296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorbetaOx
Description: Fluorine 18-labeled FluorbetaOx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorbetaOx
Description: Fluorine 18-labeled FluorbetaOx
Study: NCT04027049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine cycle ergometry of the lower extremities
Description: The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
Study: NCT02538419

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Peer Support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Individual Education
Study: NCT03256903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
Study: NCT04189653

Intervention type: OTHER
Intervention: Continuous Monitoring
Description: Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
Study: NCT03204799

Intervention type: OTHER
Intervention: Metformin
Description: newly diagnosed type 2 diabetes patients who start to metformin monotherapy

Intervention type: OTHER
Intervention: Metformin
Description: newly diagnosed type 2 diabetes patients who start to metformin monotherapy

Intervention type: OTHER
Intervention: Metformin
Description: newly diagnosed type 2 diabetes patients who start to metformin monotherapy

Intervention type: OTHER
Intervention: Metformin
Description: newly diagnosed type 2 diabetes patients who start to metformin monotherapy

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy

Intervention type: DRUG
Intervention: ezetimibe
Description: newly diagnosed dyslipidemia patients who start to ezetimibe therapy

Intervention type: DRUG
Intervention: ezetimibe
Description: newly diagnosed dyslipidemia patients who start to ezetimibe therapy

Intervention type: DRUG
Intervention: ezetimibe
Description: newly diagnosed dyslipidemia patients who start to ezetimibe therapy

Intervention type: DRUG
Intervention: ezetimibe
Description: newly diagnosed dyslipidemia patients who start to ezetimibe therapy
Study: NCT01725230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: 100-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: 100-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40-mg tablet
Study: NCT02752958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% w/w (weight per weight) stannous fluoride
Study: NCT00883870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Intramuscular injection
Study: NCT02927080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACE-083 or placebo
Description: Recombinant fusion protein or normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACE-083 or placebo
Description: Recombinant fusion protein or normal saline.
Study: NCT04040478

Intervention type: DEVICE
Intervention: Transcutaneous monitoring
Description: Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery.

Intervention type: DEVICE
Intervention: Transcutaneous monitoring
Description: Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery.
Study: NCT01382056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control foods
Description: pulse-free control foods consumed daily, 5 days per week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed bean (higher amount)
Description: 0.6 cup of mixed beans consumed 5 days per week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed beans (lower amount)
Description: 0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
Study: NCT01448785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: abiliti system implant
Description: Subjects will receive implanted abiliti System.
Study: NCT02837094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C19-A3 GNP
Description: C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
Study: NCT02300584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad
Description: a tablet computer with an internet connection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad
Description: a tablet computer with an internet connection
Study: NCT01448785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric band (Allergan Lap Band)
Description: Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
Study: NCT02030080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams
Study: NCT04076319

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAPABLE: Community Aging in Place-Advancing Better Living for Elders
Description: CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations.
Study: NCT01821521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_L20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoloc 40mg
Study: NCT03205033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 20 MG Oral Capsule
Description: 1 capsule/day 1 hour before go to bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule/day 1 hour before go to bed
Study: NCT01497691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV (PALMtop PTV)
Description: PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIPPV (PALMtop PTV)
Description: PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric CO2 (NM3)
Description: The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Volumetric CO2 (NM3)
Description: The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.

Intervention type: DEVICE
Group type: OTHER
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
Study: NCT00371137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: two doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution
Study: NCT05237154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with intermittent fasting.
Description: Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with high-intensity interval training.
Description: Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
Study: NCT02314611

Intervention type: DEVICE
Intervention: PROFEMUR® Gladiator HA Coated Modular Femoral Stem
Description: Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
Study: NCT01108302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxytocin in Uniject
Description: 10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
Study: NCT00848705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YourWay Internet Intervention
Description: The intervention is an 11 week program that teaches problem solving of barriers to self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YourWay Internet Intervention
Description: The intervention is an 11 week program that teaches problem solving of barriers to self-management.
Study: NCT02432014

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO-PTC Group clinic-based

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO Individual home-based

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO Individual clinic-based

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as Usual
Study: NCT03055260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction cuff
Description: The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Flow restriction Cuff-Placebo
Description: The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
Study: NCT00441883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207 and Latanoprost Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% and PF-03187207 Vehicle
Study: NCT00822835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01053884

Intervention type: DRUG
Group type: OTHER
Intervention: Anidulafungin
Description: standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture.
Study: NCT02732704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Pericardial TAVR System
Description: TAVR with JenaValve Pericardial Valve and Delivery System
Study: NCT05708287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
Study: NCT01294657

Intervention type: BEHAVIORAL
Intervention: Health Education
Description: Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.

Intervention type: BEHAVIORAL
Intervention: Health Education
Description: Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.

Intervention type: BEHAVIORAL
Intervention: MAPS
Description: 12 counseling phone calls over 1 year, lasting about 20-30 minutes.
Study: NCT04205071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02024633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study: NCT01652703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT03912285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine10mg
Description: Amlodipine 10mg will be administered orally twice a day for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Losartan 100mg will be administered orally once a day for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan
Study: NCT02825992

Intervention type: DEVICE
Group type: OTHER
Intervention: AcQMap System
Description: 3D imaging and mapping system for cardiac chambers
Study: NCT01082120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Tablets orally, twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Tablets orally, twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablet oral single dose for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablet oral single dose for 10 days
Study: NCT02558140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO6874813
Description: RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
Study: NCT02030080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing of feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing of feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
Study: NCT00624819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024805A
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024805A
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024805A
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix
Description: No vaccination in this trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix
Description: No vaccination in this trial